What is the current Myelodysplastic Syndrome (MDS) Drugs market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the MDS Drugs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the MDS Drugs market?

Increasing prevalence and rising awareness are key drivers of the market.

What are the major challenges facing the MDS Drugs market?

High treatment costs and limited availability are major challenges.

Which regions are leading the MDS Drugs market?

North America and Europe are leading the market due to high awareness.

Who are the top companies in the MDS Drugs market?

Top companies include Celgene, Johnson & Johnson, and Pfizer.

What future opportunities exist in the MDS Drugs market?

Emerging markets and new drug developments offer future opportunities.

How is technology impacting the MDS Drugs market?

Advances in diagnostics and treatments are improving patient outcomes.

What is the current regulatory landscape for MDS Drugs?

Regulatory bodies are implementing policies to support new drug approvals.

What is the future outlook for the MDS Drugs market?

The market is expected to grow significantly due to increasing demand.

Myelodysplastic Syndrome (MDS) Drugs Growth Trends & Strategic Outlook 2033

Myelodysplastic Syndrome (MDS) Drugs by Application (Original, Generics), by Types (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 63

Forecast Period: 2026 - 2033

Market Size: $4300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 63

Forecast Period: 2026 - 2033

Market Size: $4300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Myelodysplastic Syndrome (MDS) Drugs Market Size | CAGR 10.2 Forecast 2033

Myelodysplastic Syndrome (MDS) Drugs Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 63

Forecast Period: 2026 - 2033

Market Size: $4300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 63

Forecast Period: 2026 - 2033

Market Size: $4300 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Myelodysplastic Syndrome (MDS) Drugs Market Overview

The Myelodysplastic Syndrome (MDS) Drugs market is a growing segment of the pharmaceutical industry, with relevance to the treatment of myelodysplastic syndrome, a group of disorders caused by poorly formed or dysfunctional blood cells. As the global Myelodysplastic Syndrome (MDS) Drugs market size is estimated to be around $1.4 billion, the growth outlook and market forecast indicate a promising future, with the industry expected to expand significantly during the forecast period from 2026 to 2033, driven by increasing prevalence of MDS and an aging population. The MDS treatment market is anticipated to grow at a CAGR of 10.3%, driven by macro drivers such as advancements in medical technology and rising healthcare expenditure.

Loading chart…

The Myelodysplastic Syndrome (MDS) Drugs market is shaped by key forces such as technology shifts towards personalized medicine, regulations supporting the development of orphan drugs, and consumer behavior driven by increasing awareness of MDS. The largest region in the MDS drugs market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare infrastructure and a growing patient population. The MDS treatment landscape is highly competitive, with major players focusing on developing innovative therapies and expanding their product portfolios through strategic partnerships and acquisitions.

Report Overview

Report Attribute	Details
Market size value in 2025	4.30 billion
Revenue forecast in 2033	9.35 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celgene; Amgen; Otsuka; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Myelodysplastic Syndrome (MDS) Drugs market is poised for significant growth, driven by increasing prevalence of MDS and rising demand for effective treatments. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and shifting competitive landscapes.

Growth Drivers2 items

Advances in gene therapy and immunotherapy are expanding treatment options for MDS patients, contributing to the growth of the Myelodysplastic Syndrome (MDS) Drugs market size

Increasing geriatric population and rising awareness about MDS are driving demand for MDS drugs, supporting the growth forecast of the Myelodysplastic Syndrome (MDS) Drugs market

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Myelodysplastic Syndrome (MDS) Drugs market, restricting market growth

Side effects and toxicity associated with existing MDS treatments are hindering patient adoption, affecting the overall Myelodysplastic Syndrome (MDS) Drugs market size

Opportunities2 items

Emerging markets and underserved populations offer significant opportunities for Myelodysplastic Syndrome (MDS) Drugs manufacturers to expand their customer base and increase market share

Collaborations and partnerships between pharmaceutical companies and research institutions can accelerate the development of innovative MDS treatments, driving growth in the Myelodysplastic Syndrome (MDS) Drugs market

Challenges2 items

The Myelodysplastic Syndrome (MDS) Drugs market is highly competitive, with established players dominating the market, making it challenging for new entrants to gain traction

Pricing pressures and reimbursement issues are affecting the profitability of MDS drug manufacturers, posing a significant challenge to the growth forecast of the Myelodysplastic Syndrome (MDS) Drugs market

Market Segmentation

Loading chart…

The Application segment of the Myelodysplastic Syndrome (MDS) Drugs market refers to the various uses of these drugs in treating different types of MDS. This segment is crucial in understanding the Myelodysplastic Syndrome (MDS) Drugs segmentation and its impact on the overall market size. The application segment is further divided into subtypes, including low-risk MDS and high-risk MDS, each with its unique treatment approach and drug requirements.

The Types segment of the Myelodysplastic Syndrome (MDS) Drugs market is categorized into several subtypes, including [object Object] and [object Object]. These subtypes are distinct in their characteristics, treatment options, and market demand. Understanding the types segment is essential for analyzing the market taxonomy and identifying opportunities for growth. The types segment contributes significantly to the overall Myelodysplastic Syndrome (MDS) Drugs market size, with each subtype having its own market share and revenue potential.

Myelodysplastic Syndrome (MDS) Drugs Segmentation Breakdown7 items

Application

Original

Generics

Types

Hypomethylating Agents

Immunomodulatory Drugs

Anti-anemics

Regional Insights

Loading chart…

The Myelodysplastic Syndrome (MDS) Drugs market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the global market, driven by key factors such as high adoption of novel therapies, favorable policies, and significant investments in research and development. The region's mature ecosystem and established infrastructure also contribute to its dominance.

The fastest-growing region is expected to be Asia Pacific, driven by increasing demographics with a high prevalence of MDS, growing infrastructure, and rising ecosystem maturity. Europe is also a significant region, with key drivers including a large patient population, favorable policies, and substantial investments in healthcare. Latin America and Middle East & Africa are expected to experience moderate growth, driven by improving infrastructure and increasing adoption of MDS treatments.

The regional forecast indicates that North America will maintain its lead, while Asia Pacific will experience rapid growth. Key drivers for each region include policies, investments, demographics, infrastructure, and ecosystem maturity. Understanding these regional factors is crucial for stakeholders to navigate the Myelodysplastic Syndrome (MDS) Drugs market growth and make informed decisions.

Competitive Landscape

The Myelodysplastic Syndrome (MDS) Drugs market is moderately consolidated, with a mix of global players and local companies competing for market share. The Myelodysplastic Syndrome (MDS) Drugs competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players dominate the market, while local companies focus on regional markets and niche products.

Companies in the MDS drugs market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Celgene: regional expansion

Amgen: innovation pipeline

Otsuka: local manufacturing

Takeda: premium pricing

Celgene: vertical integration

Takeda: OEM tie-ups

Key Myelodysplastic Syndrome (MDS) Drugs Companies4 items

Celgene

Amgen

Otsuka

Takeda

Market Ecosystem

The Myelodysplastic Syndrome (MDS) Drugs ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three primary tiers: upstream, midstream, and downstream. The upstream tier comprises technology providers and suppliers, while the midstream tier involves integrators and manufacturers, and the downstream tier includes channels and end users. Value is created and captured at each stage, with participants interacting and influencing one another to drive the development and delivery of MDS drugs.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce MDS drugs

Technology providers — offer research and development services

Distributors / channel partners — facilitate drug distribution

Service providers / after-sales — provide patient support services

Regulators/standards bodies — oversee drug approvals and compliance

End users / buyers — include healthcare providers and patients

Within the Myelodysplastic Syndrome (MDS) Drugs ecosystem, control points are primarily held by regulators and manufacturers, as they influence the adoption and development of MDS drugs. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards and approvals from regulatory bodies. Switching costs and partnerships also play a crucial role, as companies may need to adapt to changing regulatory requirements or form alliances to access new technologies. Moreover, the ecosystem may differ by region due to varying regulatory frameworks and healthcare systems, highlighting the need for a nuanced value chain analysis to understand the complex interactions and interdependencies within the MDS drugs ecosystem.

Recent Industry Insights

The Myelodysplastic Syndrome (MDS) Drugs industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between pharmaceutical companies and research institutions to develop innovative treatments. Additionally, there have been strategic mergers and acquisitions, further consolidating the market. Several product launches have also taken place, including new therapies and diagnostic tools, which are expected to drive growth in the industry.

Furthermore, regulatory changes have had a profound impact on the Myelodysplastic Syndrome (MDS) Drugs market. Shifts in consumer and enterprise trends have led to increased demand for personalized medicine and targeted therapies. Funding rounds and expansions have also been announced, providing a boost to research and development efforts. These recent developments are expected to shape the future of the Myelodysplastic Syndrome (MDS) Drugs industry trends and drive innovation in the years to come.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Myelodysplastic Syndrome (MDS) Drugs market. The market attractiveness of MDS drugs is moderate, driven by the increasing prevalence of MDS and the growing demand for effective treatments. The competitive intensity is high, with several key players competing for market share. Looking at the long-term outlook, the Myelodysplastic Syndrome (MDS) Drugs market outlook is promising, with opportunities for growth and innovation.

The innovation landscape is rapidly evolving, with a focus on developing targeted therapies and improving patient outcomes. However, the demand-supply balance is a concern, with a potential shortage of effective treatments. Key risk factors include regulatory changes, pricing pressures, and the emergence of new competitors. Overall, the MDS drugs market requires careful navigation and strategic decision-making to capitalize on opportunities and mitigate risks.

11 items

1. Executive Summary

2. Myelodysplastic Syndrome (MDS) Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Myelodysplastic Syndrome (MDS) Drugs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Myelodysplastic Syndrome (MDS) Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Original

6.1.2. Generics

6.2. Global Myelodysplastic Syndrome (MDS) Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hypomethylating Agents

6.2.2. Immunomodulatory Drugs

6.2.3. Anti-anemics

6.3. Global Myelodysplastic Syndrome (MDS) Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Myelodysplastic Syndrome (MDS) Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Myelodysplastic Syndrome (MDS) Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Myelodysplastic Syndrome (MDS) Drugs Market Competition by Key Manufacturers

8.1. Global Myelodysplastic Syndrome (MDS) Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Myelodysplastic Syndrome (MDS) Drugs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Celgene

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Amgen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Otsuka

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Takeda

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Myelodysplastic Syndrome (MDS) Drugs Market

Figure 4: Global Myelodysplastic Syndrome (MDS) Drugs Market: Drivers

Figure 5: Global Myelodysplastic Syndrome (MDS) Drugs Market: Challenges

Figure 6: Global Myelodysplastic Syndrome (MDS) Drugs Market: Trends

Figure 7: Global Myelodysplastic Syndrome (MDS) Drugs Market: Opportunity

Figure 8: Global Myelodysplastic Syndrome (MDS) Drugs Market: Restraint

Figure 9: Global Myelodysplastic Syndrome (MDS) Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Myelodysplastic Syndrome (MDS) Drugs Market Value (USD Million) By Region

Figure 15: Global Myelodysplastic Syndrome (MDS) Drugs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Myelodysplastic Syndrome (MDS) Drugs Market Value (USD Million) By Region

Figure 23: Global Myelodysplastic Syndrome (MDS) Drugs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Myelodysplastic Syndrome (MDS) Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Myelodysplastic Syndrome (MDS) Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Myelodysplastic Syndrome (MDS) Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Myelodysplastic Syndrome (MDS) Drugs Market Value (USD Million) By Region

Table 10: Global Myelodysplastic Syndrome (MDS) Drugs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Myelodysplastic Syndrome (MDS) Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Myelodysplastic Syndrome (MDS) Drugs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Myelodysplastic Syndrome (MDS) Drugs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Celgene Basic Information And Sales Area

Table 31: Celgene. Products Portfolio

Table 32: Amgen Basic Information And Sales Area

Table 33: Amgen. Products Portfolio

Table 34: Otsuka Basic Information And Sales Area

Table 35: Otsuka. Products Portfolio

Table 36: Takeda Basic Information And Sales Area

Table 37: Takeda. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Myelodysplastic Syndrome (MDS) Drugs Market Value (USD Million) By Region

Table 43: Global Myelodysplastic Syndrome (MDS) Drugs Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Myelodysplastic Syndrome (MDS) Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.30 billion
Revenue forecast in 2033	9.35 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celgene; Amgen; Otsuka; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options